NCT07167966 · Phase 2 · NOT YET RECRUITING
Alzheimer's Tau Platform: Regimen A - AADvac1
This trial is testing AADvac1, a vaccine designed to target tau protein, a key driver of Alzheimer's damage. It tests AADvac1 alone and combined with donanemab, an anti-amyloid antibody. Participants are adults aged 50 to 80 with very early or preclinical Alzheimer's. This is a Phase 2 trial, meaning researchers are still gathering evidence on whether it works and whether it is safe.
You may qualify if
- No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT06957418).
You're excluded if
- No additional exclusion criteria beyond the exclusion criteria specified in the Master Protocol (NCT06957418).
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-06